Arkolith/Insider Trading/ATRA/Form 4

Grant-Huerta Yanina

Chief Accounting OfficerAtara Biotherapeutics, Inc. (ATRA) · full profile →Form 4 · filed Mar 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$11K
Net Open-Market Flow
-$11K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)377$5.08$2K32K
Mar 2, 2026Sell(S)2K$5.08$8K32K
Mar 2, 2026Sell(S)24$5.08$12234K
Mar 2, 2026Sell(S)100$5.08$50832K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000905148-26-001144) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML